Episodes

  • Brazil's ANVISA Digital Chaos: Pure Global on High-Risk Device Submission Secrets

    Brazil's ANVISA Digital Chaos: Pure Global on High-Risk Device Submission Secrets
    Mar 1 2026
    In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market. We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil. Key Questions Answered: 1. What are the three biggest technical mistakes companies make on the new ANVISA portal? 2. How does this digital shift affect submission timelines for Class III and IV devices? 3. Are there any unannounced changes to the technical dossier requirements? 4. How can you leverage this change to potentially speed up your approval process? 5. What does this move signal about ANVISA's long-term regulatory strategy? 6. Is your local distributor truly equipped to handle this level of regulatory complexity? 7. How will this impact foreign manufacturers compared to local Brazilian companies? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at info@pureglobal.com or learn more by visiting https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.

    Pure Global: Brazil's AI MedTech Brief—Decoding ANVISA's Sudden SaMD Rule Shift.
    Feb 28 2026
    This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market. **Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality? **Key Questions Answered:** * What specific cybersecurity standards has ANVISA now mandated for all SaMD products? * How does the new guidance re-classify your AI-powered medical software? * Are your existing clinical validation studies sufficient for the new Brazilian requirements? * What are the three most common documentation pitfalls for foreign firms under the new guidelines? * Why is appointing a local Brazil Registration Holder now more critical than ever? * How can you turn Brazil's tough new regulations into a strategic advantage? At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil & Mexico's MedTech Manufacturing - The Local Production Gambit.

    Pure Global: Brazil & Mexico's MedTech Manufacturing - The Local Production Gambit.
    Feb 27 2026
    This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region. What you'll learn in this episode: - Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America? - What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico? - How can a company leverage local manufacturing to gain a competitive advantage? - What is the number one mistake companies make when aligning with ANVISA's manufacturing practices? - Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices? - How does in-country production change the strategy for post-market surveillance? - What specific government incentives are most attractive for new MedTech manufacturers in 2026? Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Cracking Brazil's New MedTech Cybersecurity Code - ANVISA's Unexpected Hurdle.

    Pure Global: Cracking Brazil's New MedTech Cybersecurity Code - ANVISA's Unexpected Hurdle.
    Feb 26 2026
    Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for. This podcast episode breaks down what the new rules demand and explores the strategic implications for companies operating in Latin America's largest market. We analyze the specific requirements, the reasons behind this abrupt shift, and how it will reshape the competitive landscape for both local and international MedTech firms. **Key Takeaways:** * What are the three core technical requirements of ANVISA's new cybersecurity rule? * How does this new mandate affect devices already on the Brazilian market versus new submissions? * Why is this change happening now, and is it part of a larger LATAM regulatory trend? * What are the biggest compliance blind spots for foreign manufacturers entering Brazil? * Can proactive compliance with this new rule become a competitive advantage? * How will this impact the device registration timeline and budget for 2026? * What specific documentation, like a Software Bill of Materials, is now non-negotiable? Is your MedTech device ready for Brazil's new cybersecurity landscape? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI to streamline your market access and ensure you stay ahead of critical changes like this. Don't let regulatory surprises derail your strategy. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules

    Pure Global: Brazil's MedTech Fast-Track - The Hidden Cost of ANVISA's New Rules
    Feb 25 2026
    This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market. Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden? Key Takeaways: - What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize? - How does this new rule change the submission strategy for Class III and IV devices in Brazil? - What are the unwritten expectations for post-market surveillance for fast-tracked devices? - How can you prepare a real-world data collection plan for the Brazilian market? - Does this regulatory shift in Brazil signal a wider trend across Latin America? - What are the biggest compliance risks for companies under this new paradigm? - How do you manage technical dossier requirements when leveraging a foreign approval? - What are the key operational costs associated with these new post-market rules? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's New Device Regs & The Risk Management Blind Spot.

    Pure Global: Brazil's New Device Regs & The Risk Management Blind Spot.
    Feb 24 2026
    This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance. We explore the specific new requirements for high-risk devices, software, and the increased demand for locally relevant clinical data. This episode is essential for any MedTech company currently in or planning to enter the Brazilian market, as non-compliance with these new rules could lead to significant delays and rejections. **Case Study:** A European MedTech company, confident with their CE-marked cardiac monitoring software, submits to ANVISA. They are unexpectedly rejected. The reason? Their risk management file, which was perfectly acceptable for the EU, failed to meet Brazil's new, stringent requirements for post-market data collection and cybersecurity vulnerability monitoring. Their market entry is now delayed by at least a year, forcing a costly overhaul of their compliance documentation. **What You'll Learn:** - What specific event triggered ANVISA's major regulatory overhaul last week? - How does the new 'lifecycle' approach to risk management change your submission strategy? - Are your existing international clinical studies still valid under the new rules? - What are the three new documentation requirements for Software as a Medical Device (SaMD)? - Why might your current Quality Management System be non-compliant in Brazil right now? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market access strategy to local representation, using advanced data tools to streamline your path to compliance in over 30 markets, including Brazil. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can help.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's AI MedTech Gambit—Navigating ANVISA's New Fast-Track Paradox.

    Pure Global: Brazil's AI MedTech Gambit—Navigating ANVISA's New Fast-Track Paradox.
    Feb 23 2026
    This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just launched a new, expedited approval pathway for AI-powered medical software, potentially slashing market entry timelines. This episode breaks down the immense opportunity this presents for MedTech innovators looking to enter Latin America's largest market. But there's a critical catch. This accelerated access comes with a new, aggressive post-market surveillance system that demands continuous real-world data reporting. We explore this paradox: while the front door is easier to open, the rules for staying inside have become far more complex. We discuss what this means for manufacturers, from operational burdens to the risk of registration suspension. **Key Takeaways:** * What specific change did ANVISA just implement for AI-powered medical software? * Why is faster approval only half the story for manufacturers entering Brazil? * What are the new, stringent quarterly data reporting requirements? * How does this shift the regulatory burden from pre-market to post-market? * What kind of operational systems must companies now build to ensure compliance? * Which foreign approvals can be leveraged for this new fast-track process? * Could this new Brazilian model become a blueprint for other LATAM countries? At Pure Global, we specialize in navigating these complex regulatory landscapes. From initial market strategy and registration to fulfilling rigorous post-market surveillance requirements, our local experts and advanced AI tools ensure you can access and maintain your presence in over 30 global markets, including Brazil. Get in touch with us to future-proof your MedTech products in Latin America. Contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Brazil's SaMD Shake-Up - Navigating ANVISA's Unseen AI Hurdles

    Pure Global: Brazil's SaMD Shake-Up - Navigating ANVISA's Unseen AI Hurdles
    Feb 22 2026
    This week on LATAM MedTech Insights, we analyze the seismic new draft regulation from Brazil's ANVISA that is set to overhaul the rules for Software as a Medical Device (SaMD). This proposal introduces stringent new requirements for AI technologies and local data management, promising to reshape market access for all foreign MedTech companies targeting Brazil. We dive into the real-world impact by examining the case of a European AI diagnostics firm. Their expansion strategy, once clear, is now facing critical roadblocks due to unexpected demands for in-country clinical studies and data hosting, threatening significant delays and cost overruns. This story is a crucial lesson for any innovator looking to enter Latin America's most complex market. Key Takeaways: - Why is ANVISA suddenly proposing a major revision to its two-year-old SaMD regulation? - What are the specific new cybersecurity and data hosting rules for AI medical devices? - Will your existing FDA clearance or CE Mark still be enough for your software registration in Brazil? - What defines a "representative Brazilian population" for the new mandatory clinical validation studies? - How can you submit feedback on this draft regulation before it becomes law? - What strategies can turn these new regulatory barriers into a competitive advantage? - How should this change affect your company's five-year expansion plan for Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline global market access. Whether you are navigating new draft regulations or planning a multi-market launch, we build efficient pathways for your products. Confused about the new ANVISA rules? Contact us at info@pureglobal.com or visit https://pureglobal.com/ for a strategic consultation.
    Show More Show Less
    2 mins